Iterum Therapeutics Plc (ITRM) Stock Price, Quote & News

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 903 8354

Website: www.iterumtx.com

Address:

3 Dublin Landings, North Wall Quay, Dublin, Ireland

Nikithos Nov. 14 at 9:07 PM

$ITRM To any vote it will be a fat NO. Before asking more money from retail BOD should show some respect and demonstrate they are able to maintain the pps at a decent level. Asking for more dilution at ATL is immoral and shameless.

0 · Reply

donman150 Nov. 14 at 9:05 PM

$ITRM Damn, what a close. I'll say it. Fuck you Corey Fishman.

0 · Reply

InvestorCenterNYC Nov. 14 at 9:04 PM

$ITRM Absolute disaster. There is no catalyst that will push the price up now. Next news is another offering and/or a vote to RS. I do find it funny though that the doctor on this board says critics don't know what they are talking about, yet the ITRM board has got doctors on it and they aren't buying this either. Oh no wait, Dunne bought 15,000 shares, that's right. What a whale. Probably less than a day's pay.

0 · Reply

Alder77 Nov. 14 at 8:59 PM

$ITRM unfortunately we will get to 0.3

0 · Reply

RonBurgundysBroker Nov. 14 at 8:55 PM

$ITRM Basically played out like the tutes knew it would. Why didn’t they buy in? They knew the numbers. They have incredible resources and have all the intel. Something needs to give here because they don’t have enough money to operate another 6 months and nobody is buying a pharmaceutical company that does $15 mil a year except Pfizer who probably already bought it for $20 mill.

2 · Reply

Grego3112 Nov. 14 at 8:54 PM

$ITRM Bonne nuit Venice

0 · Reply

Alder77 Nov. 14 at 8:41 PM

$ITRM If they play the same trick on us as yesterday, we could collapse at the end. Just for fun, I placed another large order at 0.45. They are trying every way to break 0.48 and they do it.

1 · Reply

gandolf63 Nov. 14 at 8:34 PM

$ITRM never on e thought we would be at 48 cents a year after approval

1 · Reply

Zlab_Investor Nov. 14 at 8:32 PM

$ITRM .45 today: .40 Monday??

0 · Reply

GatorMcKlusky Nov. 14 at 8:26 PM

$ITRM Ok I can't look at this anymore. I'm checking out. Good game guys! We'll get 'em tomorrow!

0 · Reply

Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript

Nov 14, 2025, 7:00 AM EST - 9 hours ago

Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Nov 7, 2025, 8:00 AM EST - 7 days ago

Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

Oct 14, 2025, 8:30 AM EDT - 4 weeks ago

Iterum Therapeutics to Present Data at IDWeek 2025

Sep 19, 2025, 8:00 AM EDT - 2 months ago

Iterum Therapeutics Provides Business Update

Aug 20, 2025, 8:00 AM EDT - 3 months ago

Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.

Aug 5, 2025, 4:58 PM EDT - 3 months ago

Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 7:00 AM EDT - 3 months ago

Iterum Therapeutics Reports Second Quarter 2025 Financial Results

Jul 29, 2025, 8:00 AM EDT - 3 months ago

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 2, 2025, 4:30 PM EDT - 4 months ago

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

Jun 25, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

Jun 11, 2025, 7:00 AM EDT - 5 months ago

Iterum Therapeutics Announces Partnership for Commercialization Services

May 19, 2025, 7:00 AM EDT - 6 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note

May 13, 2025, 1:44 PM EDT - 6 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:00 AM EDT - 6 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 months ago

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 30, 2025, 4:30 PM EDT - 7 months ago

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Apr 29, 2025, 8:00 AM EDT - 7 months ago

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 14, 2025, 8:00 AM EDT - 7 months ago

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics

Feb 7, 2025, 10:20 AM EST - 10 months ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 7:00 AM EST - 10 months ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 31, 2025, 8:00 AM EST - 10 months ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025

Nov 21, 2024, 8:30 AM EST - 1 year ago

Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 14, 2024, 1:14 PM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:00 AM EST - 1 year ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 10:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)

Oct 28, 2024, 5:00 AM EDT - 1 year ago

Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 11:03 AM EDT - 1 year ago

Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024

Oct 9, 2024, 5:00 PM EDT - 1 year ago

Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit

Sep 6, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Aug 6, 2024, 5:30 PM EDT - 1 year ago

Iterum Therapeutics Announces Expiration and Results of Rights Offering

Aug 2, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering

Jun 21, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 31, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

May 13, 2024, 9:49 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports First Quarter 2024 Financial Results

May 6, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 21, 2024, 4:30 PM EDT - 1 year ago

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

Jan 30, 2024, 7:00 AM EST - 1 year ago

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Nikithos Nov. 14 at 9:07 PM

0 · Reply

donman150 Nov. 14 at 9:05 PM

$ITRM Damn, what a close. I'll say it. Fuck you Corey Fishman.

0 · Reply

InvestorCenterNYC Nov. 14 at 9:04 PM

0 · Reply

Alder77 Nov. 14 at 8:59 PM

$ITRM unfortunately we will get to 0.3

0 · Reply

RonBurgundysBroker Nov. 14 at 8:55 PM

2 · Reply

Grego3112 Nov. 14 at 8:54 PM

$ITRM Bonne nuit Venice

0 · Reply

Alder77 Nov. 14 at 8:41 PM

$ITRM If they play the same trick on us as yesterday, we could collapse at the end. Just for fun, I placed another large order at 0.45. They are trying every way to break 0.48 and they do it.

1 · Reply

gandolf63 Nov. 14 at 8:34 PM

$ITRM never on e thought we would be at 48 cents a year after approval

1 · Reply

Zlab_Investor Nov. 14 at 8:32 PM

$ITRM .45 today: .40 Monday??

0 · Reply

GatorMcKlusky Nov. 14 at 8:26 PM

$ITRM Ok I can't look at this anymore. I'm checking out. Good game guys! We'll get 'em tomorrow!

0 · Reply

Alder77 Nov. 14 at 8:22 PM

$ITRM In your opinion, after this fantastic week ended at an all-time low, What will happen next week and the weeks to come without any catalysts or news coming? How long will it take to reach 0.3 or 0.2? With this dilution rate, I think it will be before the end of November, so the RS problem will be brought forward to before Christmas, the ideal time to receive the gift from the damn Fishman. I'm not kidding, what should we be seeing value increase on in the next few days, other than short-covering?

1 · Reply

TheDuck23 Nov. 14 at 8:20 PM

$ITRM dont be a absolute idiot ! VOTE NO

0 · Reply

Drewcifer808 Nov. 14 at 8:05 PM

$ITRM ok you guys talked me into i got a starter going on that dip

1 · Reply

iambaron Nov. 14 at 8:01 PM

$ITRM so we can cut our burn rate down quite a bit by lowering salaries or using it to absorb your ATM… half of that can buy 3m shares dumped atm at these prices

1 · Reply

DeanCuratolo Nov. 14 at 8:00 PM

$ITRM So, has there been an answer to who bought those 5,000,000 shares at the below market price of .90 4 months ago?

2 · Reply

Shawshank256 Nov. 14 at 7:59 PM

$ITRM Ceo +Judy make almost 3mil/y .Untill i see them buying shares and sticking their neck out alongside investors i am voting FCK NO . Sell it for whatever or find non dilutive option .

0 · Reply

Alder77 Nov. 14 at 7:59 PM

$ITRM If there are interested parties, do a private placement, don't issue 80 million shares on the open market, allowing the value to collapse by 80%.

1 · Reply

dthomps8989 Nov. 14 at 7:53 PM

$ITRM Part 2- When management requests, I will be voting to approve an increase in authorized shares. I’m not trying to sway anyone’s opinion on that matter, just giving my opinion on what has happened and what is happening in the future. In my opinion, had those shares been approved, innoviva would be a majority owner, and we would have enough funds to expand commercialization.

1 · Reply

dthomps8989 Nov. 14 at 7:52 PM

$ITRM Part 1- I think the shareholders (including myself) made a mistake not voting to approve increasing authorized shares. I found it odd at the time that they even requested more shares, there was still so many available. But there wasn’t more than 50%. Many companies like innoviva like to take majority positions in things before acquiring them. They currently own ~70% of ARMP and owned around 60% of entasis before they acquired them. During the Q2 earnings call Judy said if we do not vote to increase authorized shares it will be more dilutive. Meaning now they have to keep hitting the atm to fund commercialization instead of (possibly) a company taking a majority stake and having enough funds to keep going with commercialization. Managements tone for this earnings call sounded like a team that was very careful with the capital that they had and were trying to conserve it. They did not sound like they wanted to dilute shareholders to oblivion.

1 · Reply

I_am_Sparta Nov. 14 at 7:46 PM

$ITRM All Time Low after All Time Low 🤣💩 when delisting 😎

0 · Reply

GatorMcKlusky Nov. 14 at 7:44 PM

$ITRM Just so you know there are a lot of fake walls up. I just knocked down a 800 share wall at .4844 on the XNMS by buying ONLY 5 SHARES. That's how they roll with fake walls, short and distort, etc.

0 · Reply

Tonyboner Nov. 14 at 7:39 PM

$ITRM Longs just don't get it, there will be no buy out and no one to save you.

1 · Reply

Market Cap	28.80M
Revenue (ttm)	0.00
Net Income (ttm)	-24.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-5.31

Volume	2,495,935
Avg Vol	784,290
Day's Range	N/A - N/A
Shares Out	48.05M
Stochastic %K	21%
Beta	3.09
Analysts	Strong Sell
Price Target	$7.00